P3 Health Partners Q1 revenue up 29% to $388.5M; appoints Dr. Aric Coffman as CEO

P3 Health Partners Inc.

2024-Q1 EPS reported -$0.16 revenue$388,488,000

Total revenue $388.5M (+29% YoY); capitated revenue $384.1M; net loss improved to $49.6M from $52.4M.
Medical margin $36.6M vs $39.2M prior year; gross profit fell to $6.4M from $16.5M.
Reaffirms FY2024 guidance: revenue $1.45-1.55B, medical margin $230-250M, adjusted EBITDA $20-40M.
Dr. Aric Coffman appointed CEO; company anticipates reaching adjusted EBITDA positive in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

P3 Health Partners Inc. updated its first quarter ended March 31, 2024 guidance (reaffirmed).

Period: first quarter ended March 31, 2024
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On May 8, 2024, P3 Health Partners Inc. (the “Company”) announced its financial results for the three months ended March 31, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Report”).

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

P3 Health Partners Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-021663

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.